Novartis announces positive results from phase III study of fingolimod in children & adolescents with MS
Novartis has announced positive topline results from the phase III PARADIGMS study, investigating the safety and efficacy of oral oncedaily fingolimod in children and adolescents (ages 10 to 17) with multiple Novartis' $475,000 cancer breakthrough heralds new era of cures
Novartis's arrangement to pay only if patients respond to the drug as a huge breakthrough New Novartis drug takes aim at tough-to-treat malaria
Novartis is taking aim at the drug-resistant malariaa growing global problemby launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and... Submission Of 69Th Annual Report For The Financial Year 2016-17
Apropos the captioned subject and references quoted above, we enclose herewith soft copy of 69th Annual Report for the Financial Year 2016-17. Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Novartis India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Scrutinizer's Report
Enclosed is the information in terms of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer's Report as per Section 109 of the Companies Act, 2013, in relation to the Annual General Meeting of Novartis India Limited held on July 28, 2017. The Board of Directors at its meeting held on July 27, 2017 has authorised Mr. Trivikram Guda, Company Secretary and Compliance Officer of the Company to declare the voting results. Outcome of AGM
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed a summary of the proceedings of the 69th Annual General Meeting of the Company held on July 28, 2017 in Mumbai. Outcome of Board Meeting
We refer to our letter dated July 19, 2017, informing you of our Board Meeting that was scheduled for today. Please note that the Board of Directors of Novartis India Limited met today and considered financial results of the Company for first quarter ended June 30, 2017. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 3:15 p.m.... Outcome of Board Meeting
We refer to our letter dated July 19, 2017, informing you of our Board Meeting that was scheduled for today. Please note that the Board of Directors of Novartis India Limited met today and considered financial results of the Company for first quarter ended June 30, 2017. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 3:15 p.m.... Shareholding for the Period Ended June 30, 2017
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here